Matricelf : INVESTORS PRESENTATION

Forward Looking Statement and Disclosure

This presentation was prepared by Matricelf Ltd. (The "Company"), as a general introductory presentation. As such, the information it includes is non-exhaustive and does not cover all the information about the Company and its operations. Therefore, this presentation is not intended to replace any need to review the Company's reports as published from time to time, including any supplementary prospectus of the Company. The information included in this presentation does not purport to survey or include all the information that could be relevant for the purpose of reaching any conclusion related to investment in the securities of the Company. The Company is also not obligated to update or change the information included in this presentation so that it reflects events, additional editing, processing, or segmentation that may differ from the current depiction in this presentation or any change that may take place after the date of its preparation. This presentation includes forward-looking information, as defined in the Securities Law 1968 including outlooks, evaluations, estimates, and other information related to the events and matters that will take place or may take place in the future, including with regard to the outlook on income and profitability, whose occurrence is not certain and is not under the exclusive control of the Company. Forward-looking statements in the presentation are based on estimates and assumptions of the management of the Company as of the date of preparation of the presentation, which are uncertain by their nature, due to their dependence on the risks inherent in the Company's operations, and which are not under the Company's control, each of which, or a combination thereof, is liable to negatively impact the results of the Company and, consequentially, the realization of these estimates and outlooks. The presentation includes statistical data and published information that were published by third parties, the content of which was not verified by the Company, and the Company is not responsible for their validity. The information included in the presentation does not constitute a proposal or invitation to make an offer to purchase the Company's securities.

Unique regenerative medicine company specializing in tissue engineering utilizing autologous cells & tissues

Two platform technologies

First product in development

✓ Generation of autologous engineered tissues

✓ Autologous engineered neural tissue to repair paralysis

Extensive IP - 6 patent families ✓ Two issued patents*

✓ Volumetric 3D bioprinting

✓ Unique solution for spinal cord injury, a major unmet medical need

✓ Active prosecution of the portfolio

* (1) Omentum-based scaffold and delivery system (EU) Publ. #: 3013380, (2) Particles comprising decellularized omentum (USA&EU), Publ. #: 2018-0361023-A1 & Publ. #: 3389678

Technology

a

Platform

Engineered tissue

Generation of autologous 3D-engineered tissues utilizing the patient's own induced Pluripotent Stem Cells and Extracellular Matrix

Generation of complex and volumetric tissues utilizing 3D bioprinting techniques*

* Early development stage

Extensive IP, comprising 6 patent families, which cover the compositions and methods of manufacture relevant to the company's therapeutic modality and the use of the modality in specific indications.

Intellectual property

Matricelf aspires to rectify this devastating condition by restoring the "missing piece" in the damaged spinal cord.

First Indication:

Traumatic spinal cord injury

Every day, ~700* individuals worldwide injure their spinal cords, resulting in varying levels of paralysis.

Humanity has succeeded in reaching space, but we still reaching space, but we still haven't managed to bridge the two centimeters of an injured two centimeters of an injured spinal cord spinal cord

* World Health Organization (WHO):https://www.who.int/news-room/fact-sheets/detail/spinal-cord-injury

Humanity has succeeded inhaven't managed to bridge the

Yariv Bash, Co-founder, SpaceIL

Spinal Cord Injury - the metrics

* Jain NB, Ayers GD, Peterson EN, et al. Traumatic spinal cord injury in the United States, 1993-2012. JAMA. 2015;313(22):2236-2243 ** World Health Organization (WHO):https://www.who.int/news-room/fact-sheets/detail/spinal-cord-injury*** Each year ~650 individuals at the age of ~25 become quadriplegic due to spinal cord injury; The Miami Project to Cure Paralysis & SCIMS 2022 Annual Report - Complete Public Version

Market size & business model

Matricelf's business model is an end-to-end product and service, covering all steps up to transplantation and rehabilitation, with centers in strategic locations

Potential market value

$15B

annually

Matricelf's go-to-market strategy, mirrors other personalized treatments and assumes ability to obtain comprehensive reimbursement coverage

* 18-60 year-old new patients (69%, NDIS Sep 2022), suffering from complete thoracic (13%) or cervical (20%) spinal cord injuries, NSCISC 2023. US, CA, EU, JP.

** As lifetime treatment cost may reach $4.8M and approved advanced therapies are available on the market for $3.1M, Matricelf estimates that a price of $1.5M would be supported by reimbursement systems.

Autologous engineered neural tissue for spinal cord injury

10